Guangdong Second Provincial General Hospital
广东省第二人民医院
Listed for 11 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Guangdong Second Provincial General Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌3 papers led
- Hepatocellular carcinoma肝细胞癌16 papers led
- Osteosarcoma骨肉瘤2 papers led
- Neuroblastoma神经母细胞瘤1 paper led
- Multiple myeloma多发性骨髓瘤3 papers led1 open trial led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎4 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
- Duchenne muscular dystrophy杜氏肌营养不良1 paper led
- Behçet disease白塞病0 papers led
Not listed for: Oesophageal squamous cell carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
23 hospitals in Guangzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led3
- Voice Changes of Patients With Nasopharyngeal Carcinoma in Eleven Years After Radiotherapy: A Cross-Sectional Study.
- Electrophysiological Changes on Laryngeal Motor Neuropathways Cause Voice Disorders for Postradiotherapy Patients with Nasopharyngeal Carcinoma.
- Glutathione-Driven Disassembly of Planar Organic Phototherapeutic Agents to Enhance Photodynamic-Photothermal Therapy Performance for Nasopharyngeal Carcinoma.
More papers found outside PubMed (not counted)10
- 1376P A comprehensive overview of immune-related adverse events induced by immune checkpoint inhibitors in nasopharyngeal carcinoma
- Efficacy and safety of induction chemoimmunotherapy versus induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A meta-analysis.
- 402O Preliminary results of phase II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)
- 455P A real-world study: Induction chemoimmunotherapy versus induction chemotherapy followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma patients with stage IVa
- Microplastics Antagonize the Therapeutic Effect of Curcumin on Nasopharyngeal Carcinoma Through Inhibiting the Apoptosis Pathway
- SICNet: Learning selective inter-slice context via Mask-Guided Self-knowledge distillation for NPC segmentation
- Enhanced Multi-Task Nasopharyngeal Carcinoma Recurrence Prediction by Knowledge Distillation with Loss-Balanced Weighting Strategy
- Risk Factors Analysis of Post Anesthesia Induction Hypotension in Patients with Recurrent Nasopharyngeal Carcinoma
- Additional file 1 of Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis
- Effect of Exercise on Sternoceleidomastoid Muscular Fibrosis after Radiotherapy for Nasopharyngeal Carcinoma Patients Analyzed by Shear-Wave Elastography
Cancer
Hepatocellular carcinoma
肝细胞癌Led 16 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
14 hospitals in Guangzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led16
- Single-cell transcriptome reveals the reprogramming of immune microenvironment during the transition from MASH to HCC.
- DEAD-box helicase 1 inhibited CD8+ T cell antitumor activity by inducing PD-L1 expression in hepatocellular carcinoma.
- Phase separation of RNF214 promotes the progression of hepatocellular carcinoma.
- Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.
- The Prognostic Value of Alpha-Fetoprotein Ratio in Patients With Resectable Alpha-Fetoprotein-Negative Hepatocellular Carcinoma.
- Low Expression of FAM96B is Associated with Poor Prognosis in Hepatocellular Carcinoma.
- Dual-targeting nanotheranostics for MRI-guided enhanced chemodynamic therapy of hepatoma via regulating the tumor microenvironment.
- Integrative analysis of disulfidptosis and immune microenvironment in hepatocellular carcinoma: a putative model and immunotherapeutic strategies.
- Integrative analysis of multi-omics data reveals inhibition of RB1 signaling promotes apatinib resistance of hepatocellular carcinoma.
- Alpha-Fetoprotein Ratio Predicts Alpha-Fetoprotein Positive Hepatocellular Cancer Patient Prognosis after Hepatectomy.
- Role of ATF3 as a prognostic biomarker and correlation of ATF3 expression with macrophage infiltration in hepatocellular carcinoma.
- SSRP1 Is a Prognostic Biomarker Correlated with CD8+ T Cell Infiltration in Hepatocellular Carcinoma (HCC).
- T-bet transduction enhances anti-tumor efficacy of IFN-producing dendritic cell (IKDC) against hepatocellular carcinoma via apoptosis induction.
- MiR-3188 regulates the proliferation and apoptosis of hepatocellular carcinoma cells by targeting CXCL14.
- Distribution of serum Thrombospondin-2, a novel tumor marker, in general population and cancer patients in China.
- Circ_0072088 promotes progression of hepatocellular carcinoma by activating JAK2/STAT3 signaling pathway via miR-375.
Cancer
Osteosarcoma
骨肉瘤Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
33 hospitals in Guangzhou for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Neuroblastoma
神经母细胞瘤Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
23 hospitals in Guangzhou for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.
- Open trials as a site
- 0
- led by another institution
14 hospitals in Guangzhou for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingTo Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2024-03
- Registry
- NCT06298266
Age 18 years to 75 years (registered criteria)
Led by Guangdong Second Provincial General HospitalGuangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led3
- Cinobufagin overcomes bortezomib resistance in multiple myeloma strains by targeting SEC62/TRPM4-mediated NECSO.
- Receptor T-Cell Chimeric Antigen Approach Used for the Prediction Model Treatment for Relapsed/Refractory Multiple Myeloma.
- Targeting ABCB6 with nitidine chloride inhibits PI3K/AKT signaling pathway to promote ferroptosis in multiple myeloma.
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Guangzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
More papers found outside PubMed (not counted)1
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 4 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
12 hospitals in Guangzhou for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Changes in the Functional Connectivity of Cerebellar Subregions in Anti-N-Methyl-d-Aspartate Receptor Encephalitis.
- Investigation of the effective connectivity between the anti-NMDAR encephalitis default mode network and the medial temporal lobe network using spectral dynamic causal modelling.
- Functional connectivity changes of the hippocampal subregions in anti-N-methyl-D-aspartate receptor encephalitis.
- White matter microstructural alterations in patients with anti-N-methyl-D-aspartate receptor encephalitis: A tract-based spatial statistics study.
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
20 hospitals in Guangzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Guangzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Guangzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Behçet disease
白塞病Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
7 hospitals in Guangzhou for Behçet disease149 hospitals in China for Behçet disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- Phase
- Phase 3
- Started
- 2023-11
- Registry
- NCT06145893
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Getting in touch
Name card to show staff or a driver
广东省第二人民医院
Guangdong Second Provincial General Hospital
广州
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Guangdong Second Provincial Hospital; GGH; Guangdong Provincial People's Hospital; Second People's Hospital of Guangdong Province